1. Home
  2. HYPR vs MXCT Comparison

HYPR vs MXCT Comparison

Compare HYPR & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyperfine Inc.

HYPR

Hyperfine Inc.

HOLD

Current Price

$1.66

Market Cap

109.7M

Sector

Health Care

ML Signal

HOLD

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$1.00

Market Cap

93.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HYPR
MXCT
Founded
2014
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
109.7M
93.0M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
HYPR
MXCT
Price
$1.66
$1.00
Analyst Decision
Strong Buy
Buy
Analyst Count
4
4
Target Price
$1.59
$5.50
AVG Volume (30 Days)
739.5K
1.0M
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
23.21
N/A
EPS
N/A
N/A
Revenue
$13,563,000.00
$33,026,000.00
Revenue This Year
$50.75
N/A
Revenue Next Year
$29.71
$18.50
P/E Ratio
N/A
N/A
Revenue Growth
5.22
N/A
52 Week Low
$0.58
$0.64
52 Week High
$2.22
$2.40

Technical Indicators

Market Signals
Indicator
HYPR
MXCT
Relative Strength Index (RSI) 59.94 56.42
Support Level $1.04 $0.77
Resistance Level $1.94 $1.81
Average True Range (ATR) 0.10 0.08
MACD -0.02 0.01
Stochastic Oscillator 64.04 55.21

Price Performance

Historical Comparison
HYPR
MXCT

About HYPR Hyperfine Inc.

Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: